As global markets navigate a period of volatility marked by inflation concerns and fluctuating interest rates, investors are seeking stability in their portfolios. In this environment, dividend stocks can offer a reliable income stream and potential for growth, making them an attractive option for those looking to balance risk with reward.
|
Name |
Dividend Yield |
Dividend Rating |
|
Peoples Bancorp (NasdaqGS:PEBO) |
5.12% |
★★★★★★ |
|
Wuliangye YibinLtd (SZSE:000858) |
3.53% |
★★★★★★ |
|
Southside Bancshares (NYSE:SBSI) |
4.53% |
★★★★★★ |
|
Padma Oil (DSE:PADMAOIL) |
7.53% |
★★★★★★ |
|
GakkyushaLtd (TSE:9769) |
4.42% |
★★★★★★ |
|
Guangxi LiuYao Group (SHSE:603368) |
3.49% |
★★★★★★ |
|
FALCO HOLDINGS (TSE:4671) |
6.66% |
★★★★★★ |
|
Premier Financial (NasdaqGS:PFC) |
4.99% |
★★★★★★ |
|
Citizens & Northern (NasdaqCM:CZNC) |
5.96% |
★★★★★★ |
|
DoshishaLtd (TSE:7483) |
3.93% |
★★★★★★ |
Click here to see the full list of 1994 stocks from our Top Dividend Stocks screener.
Let’s uncover some gems from our specialized screener.
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Bulten AB (publ) manufactures and distributes fasteners and related services for various industries including automotive and consumer electronics, operating internationally with a market cap of SEK1.50 billion.
Operations: Bulten AB (publ) generates SEK5.98 billion in revenue from its fasteners and related services across diverse industries, including automotive and consumer electronics, on a global scale.
Dividend Yield: 3.4%
Bulten’s dividend payments have been volatile over the past decade, with a payout ratio of 33.6% indicating good earnings coverage. However, cash flow coverage is less robust at 68.1%. The company’s price-to-earnings ratio of 9.8x suggests it may be undervalued compared to the broader Swedish market at 23.2x. Recent strategic ventures in Vietnam and India aim to tap into growing demand, potentially supporting future profitability and dividend stability despite high debt levels.
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Luyan Pharma Co., Ltd. focuses on the research, development, production, and sale of human health products in China with a market cap of CN¥3.16 billion.
Operations: Luyan Pharma Co., Ltd. generates its revenue through the research, development, production, and sale of human health products in China.
Dividend Yield: 3.7%
Luyan Pharma Ltd.’s dividend is well-supported by both earnings and cash flows, with a payout ratio of 32.3% and a cash payout ratio of 23.3%. Although dividends have been stable and growing, the company has only offered them for nine years. Despite recent earnings growth of just 0.7%, its dividend yield remains competitive in the Chinese market at 3.69%. However, concerns about debt coverage by operating cash flow persist.
